Orgenesis, a global biotech, has entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care cell therapy centre at the Ichilov Hospital, a multidisciplinary healthcare institution in Israel.
The parties plan to conduct collaborative cell-based research projects, initially focused on advancing the clinical development and validation of Orgenesis’ CD19 CAR-T therapies utilising its proprietary T-cell culturing and point-of-care processes and systems. The parties also plan to deploy the company’s Mobile Processing Units and Labs (OMPULs) onsite to support joint research and validation activities for advanced cell and gene therapies developed by both Orgenesis and the Tel Aviv Sourasky Medical Center. OMPULs are multi-purpose, mobile GMP facilities designed to reduce the cost of advanced therapy production and accelerate the clinical development process.
Vered Caplan, CEO of Orgenesis, stated, “It is an honour to collaborate with the Tel Aviv Sourasky Medical Center and Professor Irit Avivi, Director of Hematology, to advance the clinical development of potentially breakthrough cell and gene therapies. This latest collaboration agreement also expands our POCare Network capacity and provides further validation of the importance of our OMPULs. We remain focused on finding exceptional partners like the Tel Aviv Sourasky Medical Center to accelerate development of our broad portfolio of therapies, as well as deploy the OMPULs across our network of leading healthcare facilities and partner companies across the U.S., Europe, Asia, and the Middle East.”
Prof Eli Sprecher, Deputy Director-General for Research, Development and Innovation at the Tel Aviv Sourasky Medical Center, commented: “We are excited to partner with Orgenesis to help validate these promising immunotherapies, as well as to potentially advance the respective programs into clinical trials utilising Orgenesis’ point-of-care processes and systems. This collaboration, utilising Orgenesis’ POCare platform, reflects our commitment to helping bring potential breakthrough cell therapies to market in a cost effective, high quality and scalable manner.”